Loading
Pancreatic Function and Diabetes / Cancer, Hypoxia, and Metabolism · Journal article
Journal of Translational Medicine · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a phase 1 study of a FASN inhibitor monotherapy reporting a preliminary signal of activity in KRAS-mutant NSCLC, with 64% progression-free at >12 weeks (n=11) versus 0% in KRAS-wildtype (n=6, p<0.02). No lipid-targeted therapy has yet demonstrated clinically meaningful efficacy in unselected NSCLC patients, and clinical validation remains limited to specific molecular subtypes.
Phase 1 clinical trial. NSCLC patients stratified by KRAS mutation status. Intervention: FASN inhibitor monotherapy. n = 17.
FASN inhibitor monotherapy: 64% of KRAS-mutant NSCLC remained progression-free for >12 weeks (n=11) KRAS-wildtype NSCLC: 0% remained progression-free for >12 weeks (n=6; p<0.02) No lipid-targeted therapy has demonstrated clinically meaningful efficacy in unselected NSCLC patients to date
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preliminary finding suggests FASN inhibition may warrant further investigation in KRAS-mutant NSCLC, but the very small sample, lack of clinically meaningful efficacy in unselected patients, and phase 1 design mean this cannot guide clinical practice now. Large, controlled phase 2/3 trials in KRAS-mutant NSCLC with hard clinical endpoints are needed.
A phase 1 study reporting a preliminary signal of activity in a molecular subtype (KRAS-mutant NSCLC, n=11) with a small sample, surrogate endpoint (progression-free status at 12 weeks), and no established clinical efficacy in unselected patients.
As stated by the source record.
Quoted from the source exactly as published.
This preliminary finding suggests FASN inhibition may warrant further investigation in KRAS-mutant NSCLC, but the very small sample, lack of clinically meaningful efficacy in unselected patients, and phase 1 design mean this cannot guide clinical practice now. Large, controlled phase 2/3 trials in KRAS-mutant NSCLC with hard clinical endpoints are needed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abnormal lipid metabolism is widely recognized as a hallmark of cancer cells. In particular, non-small cell lung cancer (NSCLC) cells exhibit heightened lipid metabolic processes to meet their biosynthetic and energetic demands, while concurrently reprogramming lipid metabolism to remodel the tumour microenvironment (TME). This review details the pivotal roles of lipid metabolic reprogramming in NSCLC. First, we delineate the distinct lipid metabolic characteristics of NSCLC, exploring their regulatory mechanisms and contributions to tumour progression. Given the significant impact of lipids on the TME, we subsequently describe the intricate crosstalk between NSCLC cells and other cellular components within the TME. Furthermore, we investigate the relationship between lipid metabolism and NSCLC treatment, encompassing its role in therapeutic resistance and the potential of targeting lipid metabolism as a therapeutic strategy. Finally, we discuss the prospects and current limitations of targeting lipid metabolism in the clinical management of NSCLC. A substantial body of evidence suggests that lipid metabolic reprogramming plays a critical role in NSCLC. Median time to progression data from a phase I clinical study demonstrated that monotherapy with the FASN inhibitor showed a preliminary signal of clinical activity in KRAS-mutant NSCLC (64% remained progression-free for > 12 weeks, n = 11) compared with KRAS-wildtype NSCLC (0% >12 weeks, n = 6; p < 0.02). However, to date, no lipid-targeted therapy has demonstrated clinically meaningful efficacy in unselected NSCLC patients. Targeting dysregulated lipid metabolism in NSCLC is supported by extensive preclinical rationale, but clinical validation remains limited to specific molecular subtypes. Realising the therapeutic potential of this strategy will require addressing fundamental gaps in target selectivity, tumour-type specificity, and clinical validation. Further studies should focus on elucidating the lipid metabolic networks in NSCLC to enhance treatment outcomes for affected patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.